


5

Patent claims

sub 03

1. A pharmaceutical agent for treatment of neuropathies, characterized in that it consists, at least in part, of a compound of formula (I):



10

in which:

R^1 = C_{1-6} alkyl, optionally substituted with halogen,

R^2 = hydrogen or C_{1-4} alkyl, optionally substituted by halogen or replaced with halogen,

R^3 = C_{2-4} alkyl, optionally substituted with halogen,

15 R^4 = $SO_2NR^5R^6$,

C_{1-4} alkyl, optionally substituted with NR^5R^6 ,

CN , $CONR^5R^6$, CO_2R^7 , or halogen,

C_{2-4} -alkenyl, possibly substituted with

NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,

20 C_{2-4} -alkanoyl, optionally substituted with

NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,

R^5 and R^6 , independent of one another, represent hydrogen or C_{1-4} alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR^8)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or


25 two C_{1-4} alkyl groups,

R^7 = hydrogen, C_{1-4} alkyl, optionally, are substituted with fluorine, and

R^8 = hydrogen, C_{1-3} alkyl, or hydroxy alkyl with 1 - 4 C atoms; or of a pharmaceutically acceptable salt of such a compound.


30

5 2. The pharmaceutical agent according to Claim 1, characterized in that it consists, at least in part, of a compound of formula (Ia):




in which the groups R¹ to R³ have the meaning specified in Claim 1, and R⁹ is an alkyl group having 1 - 4 C atoms which, optionally, are substituted or replaced by halogen; or of a 10 pharmaceutically acceptable salt of such a compound.

3. The pharmaceutical agent according to Claim 1, characterized in that it consists, at least in part, of a compound of formula (III):



15 or of a pharmaceutically acceptable salt of such a compound.

5 4. A use of compounds of formula (I):



in which

R¹ = C₁₋₆alkyl, optionally substituted with halogen,

10 R² = hydrogen or C₁₋₄alkyl, optionally substituted with halogen or replaced with halogen,

R³ = C₂₋₄alkyl, optionally substituted with halogen,

R⁴ = SO₂NR⁵R⁶,

C₁₋₄alkyl, optionally substituted with NR⁵R⁶,

CN, CONR⁵R⁶, CO₂R⁷, or halogen,

15 C₂₋₄-alkenyl, optionally substituted with

NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

C₂₋₄-alkanoyl, optionally substituted with

NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

R⁵ and R⁶, independent of one another, represent hydrogen or C₁₋₄alkyl, or, together with the

20 nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-

(NR⁸)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or


two C₁₋₄alkyl groups,

R⁷ = hydrogen or C₁₋₄alkyl, optionally, substituted with fluorine, and

R⁸ = hydrogen, C₁₋₃alkyl, or hydroxy alkyl with 1 - 4 C atoms, or of a pharmaceutically

25 acceptable salt of such a compound for production of a pharmaceutical agent for treatment of neuropathies.

5. A chemotherapeutic method for treatment of neuropathies characterized by application to a patient of a pharmaceutical agent which consists, at least in part, of a compound of formula (I):



in which

10 $R^1 = C_{1-6}$ alkyl, optionally substituted with halogen,
 $R^2 =$ hydrogen or C_{1-4} alkyl, optionally substituted with halogen or replaced with halogen,
 $R^3 = C_{2-4}$ alkyl, optionally substituted with halogen,
 $R^4 = SO_2NR^5R^6$,
 C_{1-4} alkyl, optionally substituted with NR^5R^6 ,
15 CN , $CONR^5R^6$, CO_2R^7 , or halogen,
 C_{2-4} -alkenyl, optionally substituted with
 NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,
 C_{2-4} -alkanoyl, optionally substituted with
 NR^5R^6 , $SONR^5R^6$, $CONR^5R^6$, CO_2R^7 , or halogen,
20 R^5 and R^6 , independent of one another, represent hydrogen or C_{1-4} alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR^8)-1-piperazinyl or 1-imidazolyl ring which, optionally, may be substituted with one or two C_{1-4} alkyl groups,
 $R^7 =$ hydrogen or C_{1-4} alkyl, optionally, substituted with fluorine, and
25 $R^8 =$ hydrogen, C_{1-3} alkyl, or hydroxy alkyl having 1 - 4 C atoms, or of a pharmaceutically acceptable salt of such a compound.